Emalex Biosciences
Jay White has over 20 years of experience in pharmaceutical product development, including chemistry, manufacturing and controls, and non-clinical activities. He serves as the Vice President of Chemistry, Manufacturing and Controls, overseeing all aspects of drug substance and drug product research and development.
Previously, Dr. White served as Vice President, Product Development at OPKO Health Inc., Renal Division. Prior to that, he held several positions in increasing responsibility at Cytochroma Inc., including Vice President, Product Development and Vice President, Operations. During his tenure at Cytochroma and OPKO Health, Dr. White oversaw all aspects of the CMC and non-clinical programs for Rayaldee® extended-release capsules, approved by the FDA for treatment of secondary-hyperparathyroidism in Stage 3 & 4 chronic kidney disease patients with vitamin D deficiency.
Dr. White holds a B.Sc. in Biology from McMaster University and earned his PhD in Pathology from Queen’s University.
This person is not in any offices
Emalex Biosciences
Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome.